Cutaneous adverse drug reactions to modern medicines and initial experiences from a spontaneous adverse drug reaction reporting program in a tertiary care teaching hospital of Western Nepal

Journal of Pakistan Association of Dermatologists

Volumn 15, Issue 3, 2005, Pages 222-226

  Dubey, A K ^a   Prabhu, S ^a   Shankar, P Ravi ^a,b   Subish, P ^a   Prabhu, M M ^a   Mishra, P ^a  

^a MANIPAL TEACHING HOSPITAL   (Nepal)

^b MANIPAL COLLEGE OF MEDICAL SCIENCES   (Nepal)

Author keywords

Contact dermatitis; Cutaneous adverse drug reactions; Maculopapular rash; Naranjo algorithm; Pharmacovigilance

Indexed keywords

ARTICLE; CONTACT DERMATITIS; DRUG ERUPTION; ERYTHEMA; HUMAN; MACULOPAPULAR RASH; MORPHOLOGY; NEPAL; PHARMACOEPIDEMIOLOGY; SKIN MANIFESTATION; TEACHING HOSPITAL; TERTIARY HEALTH CARE;

EID: 29244439949     PISSN: 15609014     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Forrester JW. Counterintuitive behavior of social systems. MIT Technology Rev 1971; 73: 52-68.
2. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-85.
3. Bigby M, Jick S, Jick H, Amdt K. Drug-induced cutaneous reactions: a report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 1986; 256: 3358-63.
4. Leape LL, Brennam TA, Laird N et al. The nature of adverse events in hospitalized patients study II. N Engl J Med 1991; 324: 377-84.
5. Bates DW, Spell N, Cullen DJ et al. The cost of adverse drug events in hospitalized patients. JAMA 1997; 227: 307-11.
6. Classen DC, Pestotnik SL, Evans RS et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs and attributable mortality. JAMA 1999; 277: 301-6.
7. th edn. New York: McGraw-Hill; 2001. p. 336-42.
8. Kramer MS, Leventhal JM, Hutchinson TA et al. An algorithm for the operational assessment of adverse drug reactions. Background, description and instructions for use. JAMA 1979; 242: 623-32.
9. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.
10. David S, Coulson R. Community pharmacist reporting of suspected ADRs: (1) The first year of the yellow card demonstration scheme. Pharmacol J 1999; 263: 786-8.
11. Michel DJ, Knodel LC. Comparison of three algorithms used to evaluate adverse drug reactions. Am J Health System 1986; 7: 1709-14.
12. Berry LL, Segal R, Sherrin TP, Fudge KA. Sensitivity and specificity of three methods of detecting adverse drug reactions. Am J Hosp Pharm 1988; 45: 1534-9.
13. Blaiss MS, De Shazo RD. Drug Allergy Pediatr Clin N Am 1988; 35: 1131-47.
14. Rigby M. Rates of cutaneous reactions to drugs. Arch Dermatol 2001; 137: 765-70.
15. Naldi L, Conforti A, Venegoni M et al. Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol 1999; 48: 839-46.
16. http//www.WHO. The safety of medicines.html. Accessed on 15.06.2005.
17. Bates DW, Evans RS, Murff H et al. Detecting adverse events using information technology. J Am Med Inform Assoc 2003: 10: 115-28.
18. Peachey J. From pharmacovigilance to pharmacoperformance. Drug Saf 2002; 25: 399-405.